Effects of Phosphodiesterase-5 Inhibitors in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. DOI:10.1183/13993003.00214-2017
   PubMed Web of Science ®Google Scholar
• Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. DOI:10.1016/S2213-2600(17)30293-X
   PubMed Web of Science ®Google Scholar
• Soriano JB, Kendrick PJ, Paulson KR, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596. DOI:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Snell N, Strachan D, Hubbard R, et al. S32 epidemiology of chronic obstructive pulmonary disease (COPD) in the UK: findings from the British lung foundation’s ‘respiratory health of the nation’ project. Thorax. 2016;71(Suppl 3):A20.1–A20. DOI:10.1136/thoraxjnl-2016-209333.38
   Google Scholar
• Kanner RE, Connett JE, Williams DE, et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the lung health study. Am J Med. 1999;106(4):410–416. DOI:10.1016/S0002-9343(99)00056-X
   PubMed Web of Science ®Google Scholar
• Bolton CE, Bevan-Smith EF, Blakey JD, British Thoracic Society Standards of Care Committee, et al. British thoracic society guideline on pulmonary rehabilitation in adults. Thorax. 2013;68(Suppl 2):ii1–30. DOI:10.1136/thoraxjnl-2013-203808
   PubMed Web of Science ®Google Scholar
• BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD guidelines group of the standards of care committee of the BTS. Thorax. 1997;52(Suppl 5):S1–S28.
   PubMed Web of Science ®Google Scholar
• Britton M. The burden of COPD in the U.K.: results from the confronting COPD survey. Respir Med. 2003;97:S71–S79. DOI:10.1016/S0954-6111(03)80027-6
   PubMed Web of Science ®Google Scholar
• Llor C, Moragas A, Hernandez S, et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716–723. DOI:10.1164/rccm.201206-0996OC
   PubMed Web of Science ®Google Scholar
• Blanco I, Piccari L, Barbera JA. Pulmonary vasculature in COPD: the silent component. Respirology. 2016;21(6):984–994. DOI:10.1111/resp.12772
   PubMed Web of Science ®Google Scholar
• Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (viagra), in animal models of airways disease. Am J Respir Crit Care Med. 2004;169(2):227–234. DOI:10.1164/rccm.200211-1372OC
   PubMed Web of Science ®Google Scholar
• Urbanova A, Medvedova I, Kertys M, et al. Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs. Exp Lung Res. 2017;43(9–10):407–416. DOI:10.1080/01902148.2017.1386735
   PubMed Web of Science ®Google Scholar
• Zhang X, Feng Q, Cote RH. Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Invest Ophthalmol Vis Sci. 2005;46(9):3060–3066. DOI:10.1167/iovs.05-0257
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhu Y, Mao Y, et al. Efficacy and safety of Sildenafil treatment in pulmonary hypertension caused by chronic obstructive pulmonary disease: a meta-analysis. Life Sci. 2020;257:118001. DOI:10.1016/j.lfs.2020.118001
   PubMed Web of Science ®Google Scholar
• Henrie AM, Nawarskas JJ, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evid. 2015;10:99–109.
   PubMed Web of Science ®Google Scholar
• Alkhayat K, Eid M. Sildenafil citrate therapy for secondary pulmonary arterial hypertension due to chronic obstructive lung disease. Egypt J Chest Dis Tuberc. 2016;65(4):805–809. DOI:10.1016/j.ejcdt.2016.05.005
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, Cochrane Statistical Methods Group, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. DOI:10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD. 2012;9(3):268–275. DOI:10.3109/15412555.2011.651180
   PubMedGoogle Scholar
• Vitulo P, Stanziola A, Confalonieri M, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial. J Heart Lung Transplant. 2017;36(2):166–174. DOI:10.1016/j.healun.2016.04.010
   PubMed Web of Science ®Google Scholar
• Goudie AR, Lipworth BJ, Hopkinson PJ, et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2014;2(4):293–300. DOI:10.1016/S2213-2600(14)70013-X
   PubMed Web of Science ®Google Scholar
• Shrestha SK, Srivastava B, Karki M, et al. Effect of sildenafil citrate on pulmonary arterial systolic pressure and sub-maximal exercise capacity in chronic obstructive pulmonary disease. Kathmandu Univ Med J (KUMJ). 2017;15(60):271–278.
   PubMedGoogle Scholar
• Rao RS, Singh S, Sharma BB, et al. Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Indian J Chest Dis Allied Sci. 2011;53(2):81–85.
   PubMedGoogle Scholar
• Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J. 2013;42(4):982–992. DOI:10.1183/09031936.00176312
   PubMed Web of Science ®Google Scholar
• Holverda S, Rietema H, Bogaard HJ, et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther. 2008;21(3):558–564. DOI:10.1016/j.pupt.2008.01.012
   PubMed Web of Science ®Google Scholar
• Rafiei MR, Aghadavoudi O, Hojjat M. The effect of sildenafil on respiratory weaning of patients with chronic obstructive pulmonary diseases admitted to intensive care unit. Med Arh. 2012;66(2):104–106. DOI:10.5455/medarh.2012.66.104-106
   PubMedGoogle Scholar
• Salem M, Diab A, Ateya A, et al. Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension. Egypt Heart J. 2014;66(1):49–53. DOI:10.1016/j.ehj.2013.03.004
   Google Scholar
• Butrous G. The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract. 2014;2014(3):257–290.
   PubMedGoogle Scholar
• Boerrigter BG, Bogaard HJ, Trip P, et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest. 2012;142(5):1166–1174. DOI:10.1378/chest.11-2798
   PubMed Web of Science ®Google Scholar
• Enright PL. The six-minute walk test. Respir Care. 2003;48(8):783–785.
   PubMedGoogle Scholar
• Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1447–1478. DOI:10.1183/09031936.00150414
   PubMed Web of Science ®Google Scholar
• Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med. 2010;181(3):270–278. DOI:10.1164/rccm.200907-0988OC
   PubMed Web of Science ®Google Scholar
• Barberà JA, Roger N, Roca J, et al. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet. 1996;347(8999):436–440. DOI:10.1016/S0140-6736(96)90011-2
   PubMed Web of Science ®Google Scholar